Zevra Therapeutics, Inc. (ZVRA) stock
ZVRANasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 15/3060% below fair value
$9.28−0.12 (-1.28%)
Close on Nov 18, 2026Market cap $551.08MP/E 10.0Yield –
Zevra Therapeutics operating cash flow
Operating cash flow is the cash the business generates from its day-to-day operations.
Zevra Therapeutics's operating cash flow for the twelve months ending Jun 30, 2026 was $33.40M. For fiscal 2025 it was -$1.60M. The highest annual figure on record is $10.44M in fiscal 2021.
Annual operating cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$1.60M | – |
| FY2024 | Dec 31, 2024 | -$69.67M | – |
| FY2023 | Dec 31, 2023 | -$33.54M | – |
| FY2022 | Dec 31, 2022 | -$18.72M | -279.3% |
| FY2021 | Dec 31, 2021 | $10.44M | – |
| FY2020 | Dec 31, 2020 | -$1.94M | – |
| FY2019 | Dec 31, 2019 | -$23.74M | – |
| FY2018 | Dec 31, 2018 | -$54.20M | – |
| FY2017 | Dec 31, 2017 | -$33.10M | – |
| FY2016 | Dec 31, 2016 | -$29.77M | – |
| FY2015 | Dec 31, 2015 | -$20.27M | – |
| FY2014 | Dec 31, 2014 | -$14.67M | – |
| FY2013 | Dec 31, 2013 | -$4.33M | – |
Quarterly operating cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $17.03M | – |
| Q1 FY2026 | Mar 31, 2026 | $6.14M | – |
| Q4 FY2025 | Dec 31, 2025 | $5.52M | – |
| Q3 FY2025 | Sep 30, 2025 | $4.71M | – |
| Q2 FY2025 | Jun 30, 2025 | -$3.60M | – |
| Q1 FY2025 | Mar 31, 2025 | -$8.22M | – |
| Q4 FY2024 | Dec 31, 2024 | -$16.25M | – |
| Q3 FY2024 | Sep 30, 2024 | -$18.14M | – |
| Q2 FY2024 | Jun 30, 2024 | -$19.11M | – |
| Q1 FY2024 | Mar 31, 2024 | -$16.17M | – |
| Q4 FY2023 | Dec 31, 2023 | -$16.16M | – |
| Q3 FY2023 | Sep 30, 2023 | -$4.63M | – |
| Q2 FY2023 | Jun 30, 2023 | -$8.70M | – |
| Q1 FY2023 | Mar 31, 2023 | -$4.05M | – |
| Q4 FY2022 | Dec 31, 2022 | -$4.46M | – |
| Q3 FY2022 | Sep 30, 2022 | -$6.60M | – |
| Q2 FY2022 | Jun 30, 2022 | -$4.10M | -124.7% |
| Q1 FY2022 | Mar 31, 2022 | -$3.55M | – |
| Q4 FY2021 | Dec 31, 2021 | -$848.00K | – |
| Q3 FY2021 | Sep 30, 2021 | -$2.73M | – |
| Q2 FY2021 | Jun 30, 2021 | $16.60M | +657.1% |
| Q1 FY2021 | Mar 31, 2021 | -$2.59M | – |
| Q4 FY2020 | Dec 31, 2020 | -$1.06M | – |
| Q3 FY2020 | Sep 30, 2020 | -$1.05M | – |
| Q2 FY2020 | Jun 30, 2020 | $2.19M | – |
| Q1 FY2020 | Mar 31, 2020 | -$2.02M | – |
| Q4 FY2019 | Dec 31, 2019 | -$3.10M | – |
| Q3 FY2019 | Sep 30, 2019 | -$2.23M | – |
| Q2 FY2019 | Jun 30, 2019 | -$7.34M | – |
| Q1 FY2019 | Mar 31, 2019 | -$11.07M | – |
| Q4 FY2018 | Dec 31, 2018 | -$15.00M | – |
| Q3 FY2018 | Sep 30, 2018 | -$15.95M | – |
| Q2 FY2018 | Jun 30, 2018 | -$9.15M | – |
| Q1 FY2018 | Mar 31, 2018 | -$14.10M | – |
| Q4 FY2017 | Dec 31, 2017 | -$6.94M | – |
| Q3 FY2017 | Sep 30, 2017 | -$10.17M | – |
| Q2 FY2017 | Jun 30, 2017 | -$6.47M | – |
| Q1 FY2017 | Mar 31, 2017 | -$9.52M | – |
| Q4 FY2016 | Dec 31, 2016 | -$9.36M | – |
| Q3 FY2016 | Sep 30, 2016 | -$8.27M | – |
See a number that looks wrong?